Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

OLIPASS Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Shin Chung

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	12.2%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

What Kind Of Investors Own Most Of OLIPASS Corporation (KOSDAQ:244460)?

Feb 24

Should OLIPASS (KOSDAQ:244460) Be Disappointed With Their 21% Profit?

Jan 02

CEO

Shin Chung (64 yo)

no data

Görev süresi

Dr. Shin Chung, PhD is the CEO & Founder at Olipass Co., Ltd (OliPass Corporation). Dr. Chung is a high-profile expert in drug discovery and development. He served at R&D organizations including Schering-P...

OLIPASS Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

OLIPASS Corporation, Annual General Meeting, Mar 28, 2024

Recent updates

New major risk - Shareholder dilution

New major risk - Share price stability

New minor risk - Financial data availability

OLIPASS Corporation, Annual General Meeting, Mar 28, 2024

OLIPASS Corporation announced that it has received KRW 3.5 billion in funding

OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding

New major risk - Financial position

New major risk - Financial position

OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002

New minor risk - Shareholder dilution

OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding

New minor risk - Share price stability

Full year 2022 earnings released: ₩795 loss per share (vs ₩851 loss in FY 2021)

OLIPASS Corporation announced that it expects to receive KRW 2.999989475 billion in funding from BNB Asset Co., Ltd.

OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002

Full year 2021 earnings: EPS and revenues miss analyst expectations

OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002

Full year 2020 earnings released: ₩1,470 loss per share (vs ₩2,966 loss in FY 2019)

New 90-day low: ₩21,250

What Kind Of Investors Own Most Of OLIPASS Corporation (KOSDAQ:244460)?

New 90-day high: ₩32,750

Should OLIPASS (KOSDAQ:244460) Be Disappointed With Their 21% Profit?

New 90-day high: ₩27,600

New 90-day high: ₩21,550

OLIPASS Corporation announced that it expects to receive KRW 35.4996288 billion in funding from a group of investors

New 90-day high - ₩18,850

CEO

Görev süresi